SIEMENS HEALTHCARE DIAGNOSTICS INC. ADVIA CENTAUR ANTI-HEPATITIS B CORE TOTAL (HBCT); TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM)
|
Back to Search Results |
|
Model Number N/A |
Device Problem
False Negative Result (1225)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 12/12/2023 |
Event Type
malfunction
|
Event Description
|
The customer obtained a non-reactive hbc total (hbct) result on one patient sample tested with lot 188 on an advia centaur xpt instrument, that was considered discordant relative to a reactive result on a different sample from the same patient using an alternate testing method.The initial advia centaur xpt hbct non-reactive result was reported to the physician(s), who questioned the result.The physician believed the reactive result on the alternate method to be the correct result.There are no known reports of patient intervention or adverse health consequences due to this issue.
|
|
Manufacturer Narrative
|
A customer from the united states reported observation of a non-reactive hbc total (hbct) result on one patient sample tested with lot 188 on an advia centaur xpt instrument, that was considered discordant relative to a reactive result on a different sample from the same patient using an alternate testing method.The initial advia centaur xpt hbct non-reactive result was reported to the physician(s), who questioned the result.The physician believed the reactive result on the alternate method to be the correct result.Siemens healthcare diagnostics is evaluating.
|
|
Manufacturer Narrative
|
Mdr 1219913-2024-00021 was initially filed on (b)(6) 2024.Additional information (07-may-2024): a customer from the united states reported observation of a non-reactive hbc total (hbct) result on one patient sample tested with lot 188 on an advia centaur xpt instrument, that was considered discordant relative to a reactive result on a different sample from the same patient using an alternate testing method.Siemens has concluded the problem investigation.Instrument performance and reagent issues were ruled out as the hbc total (hbct) results were repeatable across multiple lots and no issues were reported with other patient samples.It is unknown if the patient was vaccinated for hepatitis b virus (hbv).Since the samples are also hbsll nonreactive and anti-hbs reactive, if the patient was not vaccinated it would indicate the patient have recovered from a previous hepatitis b virus (hbv) infection and a reactive anti-hbc result would be expected.The customer did not provide information on whether any of the samples could be tested with the advia centaur hbct2 assay.The architecture of the hbct2 assay has been designed to improve sensitivity to anti-hbc lgg, which it!he predominant antibody class in patients that have recovered from a previous hbv infection.Based on the available information, the cause of the discordant result and customer status cannot be determined, but no product problem was identified.In section h6, the codes for investigation findings, and investigation conclusions were updated.
|
|
Search Alerts/Recalls
|
|
|